AMP stands for Antibody Mediated Prevention. This is the idea of giving people antibodies to see if they will protect people from getting infected with HIV.
The AMP study is a new idea for HIV prevention that is related to what has been done in HIV vaccine research. In traditional HIV vaccine studies, people get a vaccine and researchers wait to see if their bodies will make antibodies against HIV in response. In this study, we will skip that step, and give people the antibodies directly. We will do this with an intravenous infusion, commonly known as an “IV” or “getting a drip”. This is the first study testing whether antibodies can prevent HIV infections in people.
This antibody is a broadly neutralizing antibody to HIV. Its name is VRC01. It stops HIV from binding to human T-cells by attaching to the virus and preventing it from infecting the T-cell.
(1) The VRC01 antibody is able to bind onto HIV at the (2) CD4 binding site on the gp120 protein. (3) This neutralizes HIV and prevents HIV from being able to attach to cells and infect them.